Posted in Clinical Trial on Sep 7th, 2010
Take a look at the EXAS chart from 8/19 – 9/7. A clear upward trend is easily seen. Currently I am holding both long shares and $5 October Calls. The November Calls are not yet available and I will be interested in take a position at that time. Watch for EXAS to break the $5 [...]
Posted in Breakout on Aug 9th, 2010
On July 26th we released a write-up titled “EXAS- Data Validation Study with a 10/29/10 Catalyst Date“. We followed up on July 28th with the following article “EXAS Updates – Detection Technology Achieves 100% Sensitivity“. Traders of EXAS should know that on August 10th the New York Times is publishing an article on Exact Sciences [...]
Posted in FDA Calendar on Jul 30th, 2010
EXAS – Clinical Trial Results for ColoRectal Cancer Screen 10/29/10 ALRT – FDA 510(k) Filing for Health-e-Connect (HeC) System — Health Care for Diabetes Patients. ESTIMATED Date of 3/31/11 HOLX – FDA Advisory Panel for breast cancer screening / diagnosis on 9/24/10 AZN – FDA PDUFA for Brilinta 9/16/10 MKGAY – FDA Priority Review for [...]
Posted in Clinical Trial on Jul 28th, 2010
This post is to update you on some recent developments and research done on EXAS. Clink on the title to read the article we published on Monday: “EXAS- Data Validation Study with a 10/29/10 Catalyst Date“. Today, July 28th Exact Sciences reported their Q2 earnings. Some of the highlights include:
Posted in Clinical Trial on Jul 26th, 2010
It is not often that I get excited about playing clinical trials. Generally I feel that they are too risky, as the majority of the time there is not a set catalyst date to allow for a run-up. What can happen with clinical trials and data validation studies are the results are announced unexpectedly. You [...]
Twitter
Facebook
RSS
Email